Articles for author: Russ Cohen

Russ Cohen

Most Popular

AVGO Stock Split: Broadcom’s Strategic Move for Investors AVGO Stock Split: Broadcom’s Strategic Move for Investors

This isn’t your run-of-the-mill tale of a company reshuffling its numbers; this is Broadcom taking a bold step, breaking the mold, and splitting its stock on a 10-for-1 basis. The tech landscape is abuzz as this semiconductor giant prepares for a game-changing move, slated to come into effect on July 15. Broadcom’s recent financial feat, ...

Russ Cohen

Most Popular

EchoStar’s Hughes JUPITER System Deployment by Skyband Revolutionizing Connectivity: EchoStar’s (SATS) Hughes JUPITER System Enhancing Skyband’s Network Infrastructure

An epoch-making announcement echoes through the financial cosmos as EchoStar Corporation’s SATS division at Hughes Network Systems LLC reveals a momentous collaboration with Saudi Arabia-based Luna Space Telecommunications Co. Ltd. (within the esteemed Skyband Holding company) involving the acquisition of 1,200 Hughes JUPITER Terminals and a JUPITER System Gateway from Hughes. The infusion of cutting-edge ...

Russ Cohen

Most Popular

The Defensive Liners: Steady-Eddie Stocks for Rock-Solid Returns The Defensive Liners: Steady-Eddie Stocks for Rock-Solid Returns

The Bear in Mind Mindset During tumultuous market cycles, it’s essential for investors to pivot away from flashy growth opportunities and embrace the reliability of steady stocks. Picture yourself managing a baseball team – you need a robust lineup, not just a few standout players. Likewise, in your investment portfolio, having a mix of stable ...

Russ Cohen

Most Popular

Insightful Analysis: Hyatt (H) Stock Retention Perspective The Case for Maintaining Hyatt (H) Stock amidst Market Fluctuations

Strategic Expansion Continues to Propel Hyatt (H) Performance Hyatt Hotels Corporation has strategically positioned itself for growth through an asset-light business model and aggressive expansion plans in both established and emerging markets. The company’s recent focus on forming key partnerships has further enhanced its market presence and profitability. Market Performance and Positive Outlook Hyatt’s stock ...

Russ Cohen

Most Popular

The Shifting Sands of Investment: Nvidia Stock Sales and the Rise of Ford The Shifting Sands of Investment: Nvidia Stock Sales and the Rise of Ford

There’s no doubt about the sizzling journey of Nvidia (NASDAQ: NVDA) through the era of generative artificial intelligence (AI). The GPU and AI hardware specialist has been akin to a supernova in the investment cosmos, catapulting its market capitalization into the stratosphere since the advent of ChatGPT, leaving other stocks in the dust. The meteoric ...

Russ Cohen

Most Popular

Alibaba Expands Logistics Services With Alibaba Guaranteed Expanding Horizons: Alibaba Introduces Alibaba Guaranteed

Alibaba’s international business-to-business (B2B) e-commerce arm, Alibaba.com, has unveiled Alibaba Guaranteed to cater to global small and medium-sized enterprises (SMEs). Alibaba Guaranteed serves as a platform simplifying B2B cross-border trade for SMEs, ensuring supply chain reliability. The platform offers secure sourcing of products at fixed prices, with a commitment to delivery within 72 hours. Additionally, ...

Russ Cohen

Most Popular

The Unveiling of July 26th Options for Tesla Inc

Exploring the Intricacies of Trading Opportunities Like a seasoned artist unveiling a series of intricate brushstrokes, investors at Tesla Inc welcomed the trading debut of new options slated to expire on July 26th. As the financial stage was set, one put and one call contract emerged, capturing the attention of keen-eyed market participants. A Glimpse ...

Russ Cohen

Most Popular

Dianthus Therapeutics Launches Phase 2 Trial for DNTH103 A New Chapter: Dianthus Therapeutics Initiates Phase 2 Trial for DNTH103

Grandbrothers/iStock Editorial via Getty Images Dianthus Therapeutics (NASDAQ:DNTH) revealed on Wednesday that the U.S. FDA has greenlit its investigational new drug (IND) application, paving the way for the commencement of a Phase 2 trial for DNTH103, its premier asset aimed at addressing multifocal motor neuropathy (MMN), a rare neuromuscular disorder. The Phase 2 trial, named ...